Dr. Richard Channick Addresses a New Treatment in Pulmonary Arterial Hypertension

In this video, Richard Channick, MD, Director, Pulmonary Hypertension and Thromboendarterectomy Program, Massachusetts General Hospital, Boston, MA, speaks about the use of Macitentan for the treatment of pulmonary arterial hypertension (PAH). Dr Channick says that Macitentan, compared to placebo, significantly improved morbidity in PAH. The results demonstrated in the SERAPHIN clinical trial also proved that Macitentan decreased hospitalizations in patients with PAH.

This video was taken on May 20, 2013, at the ATS 2013 International Conference in Philadelphia, PA.